Just as a disciplined soccer player might pass on a hopeful shot in favor of better chance later on, the biopharma ve...
PitchBook's Q4 report shows biopharma venture capital favoring de-risked assets over platforms and forecasts a continued, disciplined recovery in 2026.
Why it mattersPitchBook's Q4 finding favoring de-risked assets implies founders should prioritize late-stage proofpoints to attract funding.